Author Archives: Marisa Wexler MS

The Washington Research Foundation (WRF) has awarded a $250,000 grant to support the development of a novel miniprotein binder to help treat idiopathic pulmonary fibrosis (IPF). The grant was awarded to Anindya Roy, PhD, an acting instructor and senior fellow at the University of…

Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…

Vicore Pharma and Alex Therapeutics are collaborating to develop a new phone app that could help improve the mental health of people with idiopathic pulmonary fibrosis (IPF). Vicore will own all rights to the new clinical program, called VP04, in exchange for various payments and royalties to…

Treatment with Ofev (nintedanib) is safe and can preserve lung function in people with idiopathic pulmonary fibrosis (IPF) who are elderly or have several other health conditions, a new study indicates. The study, “Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who…

Axatilimab, an investigational therapy being developed by Syndax Pharmaceuticals, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for idiopathic pulmonary fibrosis (IPF). The FDA gives orphan drug status to medications that have the potential to substantially improve care…

Thanks to a $5 million donation from a grateful patient, Virginia Commonwealth University (VCU) Health is expanding its programs to treat those with lung diseases like pulmonary fibrosis (PF). After his escape from Yugoslavia in the 1950s, Bill Belanich came to the U.S., where he took a job installing…

Amgen will acquire Rodeo Therapeutics, along with its preclinical program focused on the development of potential therapies for inflammatory and fibrotic diseases like pulmonary fibrosis (PF). “With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and…

The key topics of discussion during a new webinar for people with pulmonary fibrosis (PF) focused on strategies — ranging from getting appropriate vaccines and managing individual symptoms to taking advantage of palliative and support care — for improving patient quality of life. The talk was given by Marlies…

People should be reimbursed for costs of using Ofev (nintedanib) to treat progressive fibrosing interstitial lung diseases (PF-ILD), two agencies that help to guide health policy in Canada — the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux…

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ImmunoMet Therapeutics‘ treatment candidate for idiopathic pulmonary fibrosis (IPF), IM156. The decision grants ImmunoMet permission to open studies of the therapy in people in the U.S. “FDA clearance of an IND for…